We are grateful to the Children’s Hospital of Colorado and the RTT office at Mines for a $10,000 pilot award to design mucopenetrative nanocarriers for inhalable gene therapeutics for treating cystic fibrosis (CF) and primary ciliary dyskinesia (PCD).  We are excited to collaborate with Dr. Scott Sagel, who directs the the CF and PCD Clinical and Research Centers at CHCO.